TO: Regulatory Information Service
PR Newswire
RE: PARAGRAPH 3.1.4 OF THE DISCLOSURE AND TRANSPARENCY RULES
The notifications listed below were all received under Paragraph 3.1.2 of the
Disclosure and Transparency Rules.
Diageo plc (the "Company") announces that:
1. It received notification on 10 June 2011 of the following allocations of
ordinary shares of 28 101/108 pence each in the Company ("Ordinary Shares")
under the Diageo Share Incentive Plan (the "Plan"), namely:
(i) the following director of the Company was allocated Ordinary Shares on 10
June 2011 under the Plan, by Diageo Share Ownership Trustees Limited (the
"Trustee"):
Name of Director Number of Ordinary Shares
PS Walsh 14
(ii) the following Persons Discharging Managerial Responsibilities ("PDMR")
were allocated Ordinary Shares on 10 June 2011 under the Plan, by the Trustee:
Name of PDMR Number of Ordinary Shares
N Blazquez 15
S Fletcher 14
D Gosnell 14
J Grover 14
A Morgan 14
G Williams 14
I Wright 14
The number of Ordinary Shares allocated comprises those purchased on behalf of
the employee using an amount which the employee has chosen to have deducted
from salary ("Sharepurchase") and those awarded to the employee by the Company
("Sharematch") on the basis of one Sharematch Ordinary Share for every two
Sharepurchase Ordinary Shares.
The Sharepurchase Ordinary Shares were purchased and the Sharematch Ordinary
Shares were awarded at a price per share of £12.90.
The Ordinary Shares are held by the Trustee and in the name of the Trustee.
Sharepurchase Ordinary Shares can normally be sold at any time. Sharematch
Ordinary Shares cannot normally be disposed of for a period of three years
after the award date.
2. It received notification on 10 June 2011 from Dr FB Humer, a director of
the Company, that he had purchased 642 Ordinary Shares on 10 June 2011
under an arrangement with the Company, whereby he has agreed to use an
amount of £8,000 each month, net of tax, from his director's fees to
purchase Ordinary Shares. Dr Humer has agreed to retain the Ordinary Shares
while he remains a director of the Company.
The Ordinary Shares were purchased at a price per share of £12.90.
3. it received notification on 30 June 2011 that Randy Millian, a PDMR,
exercised options on 8 June 2011 over 12,894 American Depository Shares in
the Company ("ADS")* granted on 11 October 2002 at a price per share of
$47.31 under the Diageo Share Option Plan and subsequently sold 12,765 ADS
at a price per share of $83.12. Mr Millian retains the balance of 129 ADS.
As a result of the above transactions, interests of directors and PDMRs in the
Company's Ordinary Shares and ADS (excluding options, awards under the
Company's LTIPs and interests as potential beneficiaries of the Company's
Employee Benefit Trusts) are as follows:
Name of Director Number of Ordinary Shares
Dr FB Humer 32,386
PS Walsh 667,346
Name of PDMR Number of Ordinary Shares
N Blazquez 51,377
S Fletcher 95,053
D Gosnell 72,572
J Grover 154,533
A Morgan 150,421
G Williams 183,865 (of which 6,288 are held as ADS)
I Wright 25,219
Name of PDMR Number of ADS
R Millian 10,572
J Nicholls
Deputy Company Secretary
10 June 2011
*1 ADS is the equivalent of 4 Ordinary Shares.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.